Asthma Clinical Trial
Official title:
Adapting and Expanding the Algorithmic Software Tool to Help Manage Asthma (ASTHMAXcel) for Youth With Asthma
| NCT number | NCT03930381 |
| Other study ID # | 2018-9083 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 1, 2018 |
| Est. completion date | July 1, 2023 |
| Verified date | July 2023 |
| Source | Montefiore Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This project seeks to test and refine an adapted/expanded version of a previously created ASTHMAXcel app.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | July 1, 2023 |
| Est. primary completion date | July 1, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 15 Years to 21 Years |
| Eligibility | Inclusion Criteria: - English-speaking individuals between 15-21 - Persistent asthma (diagnosis made by a healthcare provider) - On a daily controller medication - Able to give informed consent - Smartphone (iOS or Android) access Exclusion Criteria: - Use of oral corticosteroids in the 2 weeks prior to the baseline visit - Pregnancy - Severe psychiatric or cognitive problems that would prohibit an individual from understanding and completing the protocol - Patients that previously received the ASTHMA-Educator application |
| Country | Name | City | State |
|---|---|---|---|
| United States | Montefiore Medical Center | Bronx | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Montefiore Medical Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from Baseline Asthma Control to 3 Month Asthma Control | Asthma symptom burden as measured by the Asthma Control Test
Score Scale: 5 (min = worse); 25 (max = better outcome) |
Post-Refinement Baseline, 3 Months | |
| Primary | Change from Baseline Asthma Control to 3 Month Asthma Control | Asthma symptom burden as measured by the Asthma Control Test
Score Scale: 5 (min = worse); 25 (max = better outcome) |
Post-Refinement Baseline, 4 Months | |
| Secondary | Asthma Symptom Perception | Ability of participants to perceive their asthma symptoms by using the ASTHMAXcel app and a peak flowmeter | Week 2, Week 4 , Week 6 (Pre and Post Refinement) | |
| Secondary | Asthma Knowledge | Will use the Child Asthma Illness Representation Survey (AIRS) to asses patients knowledge on asthma as well as their attitudes towards their condition.
Score Scale: 4 (min = worse outcome); 20 (max = better outcome) |
Post-Refinement Baseline, 3 Month | |
| Secondary | Medication Adherence | Self-reported adherence by patient using Medication Adherence Report Scale
Score Scale: 10 (min = worse outcome); 50 (max = better outcome) |
Post-Refinement Baseline, 3 Month | |
| Secondary | Asthma Quality of Life | Quality of life of participants, measured by mini-Asthma Quality of Life Questionnaire
Score Scale: 15 (min = worse outcome); 105 (max = better outcome) |
Post-Refinement Baseline, 3 Month | |
| Secondary | Emergency Department Visits | Self-Reported Emergency Department (ED) visits | Post-Refinement Baseline, 3 Month | |
| Secondary | Patient Satisfaction | Patient satisfaction with study measured by the Client Satisfaction Questionnaire-8
Score Scale: 8 (min = worse outcome); 32 (max = better outcome) |
Post-Refinement Baseline, 3 Month | |
| Secondary | Patient Interface Satisfaction | Patient satisfaction with ASTHMAXcel app interface measured by Questionnaire for User Interface Survey (QUIS)
Score Scale: 0 (min = worse outcome); 261 (max = better outcome) Answers scale from 0 (terrible/hard to understand)) to 9 (wonderful/easy to understand) |
Post-Refinement Baseline, 3 Month | |
| Secondary | Patient Usage | Time spent on app and different screens of app, measured using Google Analytics | Baseline, 3 Month | |
| Secondary | Health Literacy | Ability for patients to comprehend Newest Vital Sign screening tool | Post-Refinement Baseline |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|